FDA Communications PR: 5 Rules for Biotech Announcements
By Kyle Porter, Executive Vice President & Managing Director.
Updated November 12, 2026
FDA communications PR is the practice of announcing drug development news without crossing FDA promotion rules or securities disclosure rules. For a biotech, that means five rules: describe results without calling an investigational drug safe or effective, match every statement to the FDA record, disclose to all investors at once, keep one source of truth, and plan for bad news before it arrives.
Last updated: November 12, 2026
On this page
What does FDA communications PR cover?
FDA communications PR covers every public statement a drug or biologics developer makes about its regulatory status, including press releases, investor decks, website copy, conference remarks and executive interviews. The work sits between two rule sets. FDA rules limit how an unapproved product can be described, and securities rules govern who hears material news and when.
A biotech press team writes for three readers at once: reporters who cover the sector, investors who trade on the news, and regulators who can read the same text. A sentence that satisfies one reader can fail another. That is why the five rules below start from the regulatory text itself, not from a style preference.
The rules apply most tightly to clinical-stage companies, where the product is still investigational. They also matter at the moment of an FDA decision, when a single announcement may be read against an FDA letter that the agency itself may publish.
Rule 1: Can an Investigational Drug Be Called Safe or Effective?
An investigational drug cannot be represented as safe or effective for the use under study in a promotional context. The rule is 21 CFR 312.7(a), which bars a sponsor, an investigator or anyone acting for them from making that representation or otherwise promoting the drug. The same section says it is not meant to restrict the full exchange of scientific information, according to the eCFR text of 21 CFR Part 312.
The practical line runs between reporting data and drawing conclusions. A release can state the trial design, the endpoint, the number of patients and what the data showed. It should not say the data prove the drug works or is safe.
The enforcement record shows where that line sits. In a summary by the law firm Arnall Golden Gregory, FDA's Office of Prescription Drug Promotion sent an untitled letter on November 1, 2019 to the sponsor of an investigational brain cancer drug. The sponsor's website said results demonstrated the antibodies were safe and effective, and the office treated those conclusory statements as promotion.
Three writing habits follow from that rule:
-
State the endpoint, the patient population and the measured result in the same sentence that makes the claim.
-
Replace verdict words such as cure, proven and breakthrough result with the number the trial actually produced.
-
Say on every page that the product is investigational and has not been approved by FDA.
Rule 2: Should Every Statement Match the FDA Record?
A biotech announcement about an FDA decision should match the FDA's own record, because the agency now publishes rejection letters. On September 4, 2025, FDA announced that it will release complete response letters promptly after it issues them to sponsors, and it posted 89 previously unpublished letters issued from 2024 onward. The FDA news release says the letters are redacted for confidential commercial information but still contain company names.
FDA's release also states a purpose that matters to communicators: ensuring that sponsors give complete and contextualized information in communications to investors and shareholders. The agency had already published more than 200 letters on July 10, 2025, according to a Holland & Knight client alert, which also noted that FDA has not defined a specific timeline for what counts as prompt. The FDA announcement of real-time letter release is the primary source.
The implication is direct. A company should write its rejection statement as if the full letter will be public. If the letter names manufacturing or data deficiencies, the announcement should not describe the outcome as minor or procedural unless the letter itself supports that reading, because a reporter can now put the two documents side by side.
Rule 3: How Does Regulation FD Affect FDA News?
Regulation FD, the SEC's selective disclosure rule, requires a public company that gives material nonpublic information to certain outsiders, such as analysts and institutional investors, to make that information public at the same time. Companies usually meet the requirement with a press release or a Form 8-K. Items 7.01 and 8.01 of Form 8-K are the items commonly used for voluntary disclosures.
Whether a given FDA event is material, and whether a mandatory 8-K item applies, is a question for securities counsel. Under the form's general instructions, mandatory items carry a four business day deadline, so the legal review has to start on the day the news arrives.
The classic risk is the analyst call. If the outcome of an FDA meeting is material, a call with an analyst the next morning cannot be the first place it appears. The press release goes out first, and any investor conversation follows the same wording.
Rule 4: Why Keep One Source of Truth Across Channels?
One source of truth means every channel repeats the same approved wording for regulatory status, trial results and timelines. The reason is that FDA does not look only at press releases. An Arnall Golden Gregory write-up of a Warning Letter from the same promotion office lists, among the concerns, a video interview with the company's then-CEO and president that was hyperlinked from the company website.
A one-page message document solves most of the problem. It holds the approved description of the product's status, the latest data in plain terms, the timeline the company has already disclosed, and the phrases it will not use. The team updates it after every data release or FDA contact, and every executive reads it before an interview, a conference panel or an investor meeting.
The same document governs older material. Website pages, conference posters and archived videos should be checked against it each quarter. For the interview side of this work, see the guide to executive media interview preparation.
Rule 5: How Should a Team Prepare for a Rejection Letter?
A prepared rejection statement is a draft written before the FDA decision date, with blanks only for the facts the letter will supply. It states what the company submitted, what FDA decided, which deficiencies the letter names, what the company will do next and when it will update investors.
That draft goes through the same medical, regulatory, legal and investor relations review as a good-news release. Writing it early removes the pressure that produces vague language on the day, and it gives the board and the investor relations lead the same text to react to. The clinical-stage biotech PR rules cover how to talk about disappointing data in more depth.
What Should an FDA Announcement Timing Table Include?
An FDA announcement timing table lists each regulatory event, what the announcement must say, who reviews it and how it reaches investors. The table below is a planning template. Securities counsel decides which events require a Form 8-K for a specific company.
EventWhat the announcement statesReviewersDisclosure route
Trial start or IND clearancePhase, indication, design, patient count, investigational statusRegulatory, medical, legalPress release, 8-K if counsel advises Topline or interim dataEndpoint, population, result, safety observations, what is not yet knownMedical, statistics, legal, investor relationsPress release before any investor call FDA designation grantedThe designation named exactly, and what it does and does not meanRegulatory, legalPress release Application accepted for reviewApplication type and any FDA action date the company has chosen to discloseRegulatory, legal, investor relationsPress release Complete response letter or approvalThe decision, deficiencies named in the letter, next steps, next update dateMedical, regulatory, legal, investor relations, boardPress release and 8-K if counsel advises, ahead of any call
What Is a Pre-Release Checklist for FDA News?
A pre-release checklist is the ordered set of checks an FDA-related announcement passes before it is published. The seven steps below fit most clinical-stage releases.
-
Confirm the exact regulatory status of the product against the FDA correspondence on file.
-
Check every result sentence against 21 CFR 312.7(a) and remove any statement that says or implies the drug is safe or effective.
-
Compare each factual statement with the source document, including any FDA letter the agency may publish.
-
Send the draft to medical, regulatory, legal and investor relations reviewers in one round, not in sequence.
-
Ask securities counsel whether Regulation FD or a Form 8-K item applies, and fix the release time.
-
Update the message document, the website and the investor deck so all three match the release.
-
Brief every spokesperson on the approved wording before the first interview or investor call.
Frequently asked questions
What does 21 CFR 312.7 prohibit?
21 CFR 312.7(a) prohibits a sponsor, an investigator or anyone acting on their behalf from representing in a promotional context that an investigational new drug is safe or effective for the purposes under investigation. The same text says the rule is not intended to restrict the full exchange of scientific information.
Are FDA complete response letters public?
FDA announced on September 4, 2025 that it will release newly issued complete response letters promptly after it issues them to sponsors. The letters are redacted for confidential commercial information, contain company names and are available through the agency's openFDA dataset.
Does Regulation FD apply to a private biotech company?
Regulation FD applies to public companies that report to the SEC, so a private biotech is outside it. A private company still has to keep its statements consistent with FDA rules, and it should check with counsel on any financing documents that carry their own disclosure terms.
Who should review an FDA-related announcement?
Medical, regulatory, legal and investor relations reviewers should all see the draft, and a public company should add securities counsel. Reviewing in one round shortens the cycle and keeps the wording consistent across the release, the website and the investor deck.
How much does biotech PR cost?
Published ranges for biotech PR retainers are collected in the guide to biotech PR retainer costs. A company choosing a firm can compare documented life sciences work in the list of biotech PR agencies compared.
What should a team do first after publishing FDA news?
The first step is to pull the company's last three FDA-related announcements and check each result sentence against 21 CFR 312.7(a). Any sentence that states or implies the drug is safe or effective gets rewritten to the measured result, and the website copy is checked against the same standard.
Follow us
LinkedIn
